Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with cervical cancer that has come back or spread to other parts of the body.
- You may have had up to 2 prior chemotherapy treatments for advanced cancer, and you may have also had immunotherapy or a drug like bevacizumab before.
- You need to have a tumor tissue sample (from a biopsy or surgery) that can be tested for PD-L1.
- You must be in generally good health (able to do daily activities) and have adequate organ function, like your kidneys, liver, and heart.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must use highly effective birth control during and for a time after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This study tests a new combination of immunotherapy drugs for cervical cancer that has spread or returned. It aims to see if the treatment can shrink tumors and improve outcomes for people whose cancer is not curable with standard treatments.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether adding two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy)—to the standard chemoradiation and brachytherapy can improve outcomes for women with high-risk locally advanced cervical cancer. The goal is to see if this combination helps control the cancer better than usual treatment.
Hear when a new Cervix Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.